Dr. Anna Belcheva, M. D.
What this data tells you about Dr. Belcheva
Dr. Anna Belcheva is a hematology & oncology specialist in Houston, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Belcheva performed 63,994 Medicare services across 1,331 unique beneficiaries.
Between the years covered by Open Payments, Dr. Belcheva received a total of $8,014 from 77 pharmaceutical and/or device companies across 397 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Belcheva is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 23,460 | $0 | $5 |
| Iron sucrose injection (Venofer) | 9,800 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 9,400 | $43 | $137 |
| Darbepoetin injection (Aranesp) for anemia | 8,040 | $2 | $20 |
| Anti-nausea injection (fosaprepitant) | 4,950 | $0 | $5 |
| Denosumab injection (Prolia/Xgeva) | 4,080 | $18 | $66 |
| Dexamethasone injection (steroid) | 1,041 | $0 | $1 |
| Complete blood count (CBC) with differential | 579 | $8 | $36 |
| Office visit, established patient (30-39 min) | 534 | $96 | $368 |
| Anti-nausea injection (Aloxi/palonosetron) | 430 | $1 | $114 |
| Administration of chemotherapy into vein, 1 hour or less | 168 | $103 | $707 |
| Blood draw (venipuncture) | 162 | $8 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 161 | $23 | $157 |
| Drug injection, under skin or into muscle | 150 | $11 | $96 |
| Injection, carboplatin, 50 mg | 133 | $2 | $300 |
| Office visit, established patient (20-29 min) | 127 | $62 | $250 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 120 | $51 | $313 |
| Injection of additional new drug or substance into vein | 102 | $12 | $108 |
| Comprehensive metabolic blood panel | 84 | $10 | $64 |
| Administration of additional new drug or substance into vein, 1 hour or less | 65 | $50 | $344 |
| Injection, diphenhydramine hcl, up to 50 mg | 57 | $1 | $7 |
| Reticulated (young) platelet measurement | 36 | $35 | $143 |
| Administration of chemotherapy into vein, each additional hour | 33 | $22 | $161 |
| New patient office visit (45-59 min) | 32 | $112 | $565 |
| Microscopic examination for white blood cells with manual cell count | 31 | $4 | $22 |
| Complete blood count (CBC), automated | 31 | $6 | $34 |
| Red blood count automated, with additional calculations | 31 | $5 | $26 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 29 | $25 | $145 |
| Unclassified drugs | 29 | $1 | $8 |
| Infusion, normal saline solution , 1000 cc | 29 | $2 | $19 |
| Irrigation of implanted venous access drug delivery device | 26 | $19 | $114 |
| Automated urinalysis | 22 | $2 | $16 |
| New patient office visit, complex (60-74 min) | 22 | $164 | $709 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Belcheva is a mixed practice specialist, with above-average Medicare volume (top 15% in TX), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Belcheva experienced with iron infusion (feraheme)?
Does Dr. Belcheva receive payments from pharmaceutical companies?
How do Dr. Belcheva's costs compare to other hematology & oncology specialists in Houston?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology